Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Please post article about the CLBS lawsuit please, My mind is blank about this??
Thank You for your post!!! This is really great news!!
I totally agree with you F1ash! Plus the doctors they have on board are some of the best in there field! I honestly do not know what is holding them back!
I think this was from phase 1, I may be wrong but there name was with phase 1 and dated 8/14!
Autologous T regulatory cells: Preliminary Phase I data
Published on Monday, August 4, 2014
Becton Dickinson and Co. (NYSE:BDX), Franklin Lakes, N.J.
NeoStem Inc. (NASDAQ:NBS), New York, N.Y.
I really am not familiar I hate to say with CLBS03, but I get the impression this is from phase 1 and not going into phase 2,
http://www.caladrius.com/development-pipeline/clbs03/
I do not think this is new cause the date says ::
Autologous T regulatory cells: Preliminary Phase I data
print
bookmark
new archives search
email to colleague
tweet this
Published on Monday, August 4, 2014
No they will not be looking for main results till then(everybody enrolled) BUT ::Further study details as provided by Caladrius Biosciences, Inc.::
Primary Outcome Measures: •Time to continuous CLI-free status
[ Time Frame: 1 year ]
[ Designated as safety issue: No ]
CLI-free is determined by assessing the Rutherford score (</=3) by the investigator and a central adjudication committee.
They will have results at one year to start to boast the PPS! I do agree it will be a while BUT the more we get going now in a few years we are going to be getting all kinds of results! We have clbs10 and clbs20 till then!
I am wondering if they will release this news around the time of earnings (Aug3 I think) to keep the stock steady!
OMG this was a excellent find Lunatick! The more I find and read the more I feel that Japan is a go! They have not announced yet but we have financials coming up I think it was Aug 3 so they may wait to keep the price from dropping! https://clinicaltrials.gov/ct2/show/study/NCT02501018
This is just so good!
Is Japan a go then???? It just dawned on me>>read the bottom!!!
https://clinicaltrials.gov/ct2/show/study/NCT02501018
Flash I can not see your post 2306??? It has no title so there is nothing to click on??
Thanks for the post I had not seen this yet!
Yes I have seen both of these! The new site is updating everything from NBS to CLBS including the videos on you tube. I know I was looking threw them the other day! So now they have the date they where updated with the views from June 2015 instead of when they where first posted! Thank You, these are good videos and from the people that missed them it is a good time to view them!
I agree! I have not let loose of mine, just holding and waiting!
I think some people are just tired of holding so long. A lot jumped in at low price and thought they would make a lot and now are moving on! MHO
That is good they are mentioning CLBS, hopefully the word starts to get around!! You found this and I do not understand why CLBS does not have things like his posted! They could just have a page of CLBS in the news! People doing DD need to see all these articles! Thank You for the post!
Yes that is ok! I posted that same article back on July 1 Here! I think it was a very good read! jca408harvard makes a lot of sense and hopefully he is right! I hope people that did not read it then read it now! The whole post is post 2203, I included the second day post of his that says how we will get to $10 by June 2016, here is the rest of the read::
jca408harvard from yahoo CLBS Message board
Good Luck Lynx5100
I was really sort of surprised when they used NWBO as a comparison! The price widely differs, I am not sure if he is saying we should be that high and if so get the press out there! Lunatick I see newbies into the stock that are saying about the one year prediction $14 how can you not buy! I know you remember 2 years ago when the prediction was at $22-27 dollars and look where we are at! They need to partner up and get this news out!
I agree! The one topic I have been on for years is CLBS(nbs) and the press! I have wrote them over and over I have posted here, there everywhere they need more press! I find and post articles all the time that they do not even post! I have written and told them when they have these stem cell meetings, summits and events just to post pictures of them talking, shaking hands, speaking! Let us know how it went, the more the name is spread the better for the company and investors! I at least would not feel like I am sitting in a dark room! There PR person SUCKS! I hope I do not get kicked out for that but it is true. I find You-tubes of them speaking but no one knows unless they go look!
Well they have stated that the money they have will take them into 2016, if they pony-up with a partner or Japan gets in this will make a difference!
If you are waiting for THE STREET to get involved they are one of the main reasons this stock went down! AF has continually bashed this stock making remarks, bashed and tore the results down! He is NO DOCTOR! Cardiologists even agreed the findings from NBS10 where great! Saving life's are there biggest agenda not SHORTING A STOCK!
It could be a long time for really good news, I have invested here long term. This is not a quick money maker by no means!
PCT mentioned in here!
Pre-Market News Analysis on: Epirus Biopharmaceuticals (NASDAQ:EPRS), Sherwin-Williams (NYSE:SHW), Allied World Assurance Co Holdings, (NYSE:AWH), ImmunoCellular Therapeutics (NYSEMKT:IMUC)
?Jul 16, 2015?Paul Bailey?Business & Finance?0
On Wednesday, Epirus Biopharmaceuticals Inc (NASDAQ:EPRS)’s shares inclined 0.14% to $7.39.
EPIRUS Biopharmaceuticals, Inc. (EPRS) and Polpharma Group declared the signing of a multi-product, multi-region profit-sharing partnershipfor select EPIRUS biosimilars, counting BOW015 (infliximab, reference biologic Remicade®), BOW050 (adalimumab, reference biologic Humira®) and BOW070 (tocilizumab, reference biologic Actemra®), representing $6 billion in innovator sales in the specified territoriesi. Polpharma Group is a leading generics company based in Poland with annual sales of about $1 billion and a strong commercial infrastructure, counting a salesforce of over 1,700 employees globally.
With EPIRUS leading the global product development and clinical programs, both parties will jointly fund clinical development and collaborate on regulatory filings in the specified territories. EPIRUS will also be responsible for process development, scale-up and manufacturing, with Polpharma Group overseeing commercialization across the territories. Clinical development costs and eventual operating profit will be split 51 percent Polpharma Group and 49 percent EPIRUS. Polpharma Group will contribute about $30 million towards clinical development costs, in addition to cover product launch costs across all three programs.
EPIRUS Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases.
Sherwin-Williams Co (NYSE:SHW)’s shares dropped -0.75% to $282.16.
The Sherwin-Williams Company (SHW) will host a live webcast to talk about the results of the second quarter 2015, to be held Thursday, July 16, 2015 at 11:00 AM Eastern Time.
The Sherwin-Williams Company develops, manufactures, distributes, and sells paints, coatings, and related products to professional, industrial, commercial, and retail customers primarily in North and South America. The company operates in four segments: Paint Stores Group, Consumer Group, Global Finishes Group, and Latin America Coatings Group. It provides architectural paint and coatings, protective and marine products, automotive finishes and refinish products, original equipment manufacturer product finishes, and related items. The company also licenses technology and trade names.
At the end of Wednesday’s trade, Allied World Assurance Co Holdings, AG. (NYSE:AWH)‘s shares dipped -0.05% to $44.26.
Allied World Assurance Company Holdings, AG (AWH) declared recently that Kim Delaney has been designated Senior Vice President, Healthcare Administration Liability Practice Lead for Allied World North America. Ms. Delaney is based in Allied World’s Farmington, Connecticut office and will report directly to Christian Gravier, President, Allied World North American Professional Lines Division. In her new role, Ms. Delaney will oversee all components of the Healthcare Administration Liability business, counting product strategy, distribution, relationship administration and administration of talent and resources.
Allied World Assurance Company Holdings, AG, through its auxiliaries, provides property, casualty, and specialty insurance and reinsurance solutions worldwide. It operates through three segments: North American Insurance, Global Markets Insurance, and Reinsurance.
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), ended its Wednesday’s trading session with 4.93% gain, and closed at $0.509.
Caladrius Biosciences, Inc. (CLBS), a cell therapy leader with a late-stage clinical program for immuno-oncology, declared recently a new Agreement between its wholly-owned partner, PCT, LLC, a Caladrius Company (“PCT”), and ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT:IMUC), a clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers.
Under this Agreement, PCT will produce ICT-107, a dendritic cell-based immunotherapy targeting six glioblastoma tumor-associated antigens, for a pivotal Phase 3 trial in patients with newly diagnosed glioblastoma. PCT has served as an external manufacturing and development provider for ImmunoCellular since 2011, counting clinical production for ImmunoCellular’s ICT-107 Phase 2 trial.
PCT will provide manufacturing services, counting processing, packaging, labelling, quality control testing, release, shipping and storage, in addition to process requalification, for ICT-107. The agreement comprises the provision of a semi-dedicated controlled environment room and staff to meet ImmunoCellular’s Phase 3 manufacturing needs. Furthermore, ImmunoCellular will make use of PCT’s capability to perform a technology transfer process to harmonize the EU and US methods of production of ICT-107.
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate comprises ICT-107, a dendritic cell (DC) vaccine that accomplished Phase II testing trials for the treatment of glioblastoma multiforme (GBM). The company also develops other therapeutic DC vaccines, such as ICT-121 to treat recurrent GBM and other solid tumor cancers; and ICT-140 for ovarian cancer.
http://www.wsnewspublishers.com/pre-market-news-analysis-on-epirus-biopharmaceuticals-nasdaqeprs-sherwin-williams-nyseshw-allied-world-assurance-co-holdings-nyseawh-immunocellular-therapeutics-nysemktimuc/1517244/
Caladrius Biosciences Receives $14.57 Average PT from Analysts (NASDAQ:CLBS)
Posted on July 16, 2015 by Stefani Robinson in Consensus Rating Articles, Investing
Caladrius Biosciences logoCaladrius Biosciences (NASDAQ:CLBS) has received a consensus recommendation of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $14.38.
CLBS has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a research note on Tuesday. Analysts at Maxim Group reiterated a “buy” rating on shares of Caladrius Biosciences in a research note on Thursday, June 25th. Analysts at Benchmark Co. lowered their price target on shares of Caladrius Biosciences from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Finally, analysts at MLV & Co. initiated coverage on shares of Caladrius Biosciences in a research note on Monday, April 6th. They set a “buy” rating and a $14.00 price target on the stock.
Shares of Caladrius Biosciences (NASDAQ:CLBS) opened at 1.90 on Monday. Caladrius Biosciences has a 52 week low of $1.80 and a 52 week high of $7.22. The stock has a 50-day moving average of $2.05 and a 200-day moving average of $2.97.
Caladrius Biosciences, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market.
http://sleekmoney.com/caladrius-biosciences-receives-14-57-average-pt-from-analysts-nasdaqclbs/351084/
Boy do I agree with you! My family has asked me all along about this stock and I have told them to hold back, till last week. I told them then the price is low and if I was going to enter it would be soon BUT probably after the financials which are coming in August, this could make the stock drop more. I like you are in a much higher price! I think the stock is the best in its field and expect a upward trend to come, WHEN I do not know. I never thought I would see $4, $3 or $2!
You should have got voting papers from your broker, I received mine a while ago.
CALADRIUS BIOSCIENCES : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
Envoyer par mail
07/15/2015 | 06:03am US/Eastern
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) Compensatory Arrangements.
2015 Equity Compensation Plan
At the Caladrius Biosciences, Inc.'s ("Caladrius Biosciences" or the "Company") 2015 Annual Meeting of Stockholders held on July 14, 2015 (the "Annual Meeting"), the Company's stockholders duly approve Caladrius Biosciences' 2015 Equity Compensation Plan (the '2015 Plan"). Persons eligible to receive options, stock appreciation rights or other awards under the 2015 Plan are those employees, consultants and directors of Caladrius Biosciences and its subsidiaries who, in the opinion of the Compensation Committee of the Company's board of directors, are in a position to contribute to the Company's success. A description of the 2015 Plan is set forth in Proposal 3 contained in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on June 8, 2015 (the "Proxy Statement"). The full text of the Amended and Restated 2009 Plan is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 5.07. Submission of Matters to a Vote of Security Holders.
The following is a brief description of each matter voted upon at the Annual Meeting (for a full description of each such matter see the Proxy Statement), as well as the final voting results with respect to each such matter:
Proposal 1. The stockholders elected one Class II director, David J. Mazzo, PhD, to serve as a director on the Company's Board of Directors until the annual meeting to be held in 2018.The final voting results with respect to the were as follows: 10,151,328 votes for; 481,726 votes withheld and 14,384,701 broker non-votes.
Proposal 2. The stockholders approved, on a non-binding advisory basis, the executive compensation of the Company's named executive officers as described in the Proxy Statement. The final voting results with respect to this Proposal were as follows: 8,061,872 votes for; 2,394,354 votes against; 176,828 votes abstaining; and 14,834,701 broker non-votes.
Proposal 3. The stockholders approved Caladrius Biosciences' 2015 Equity Compensation Plan. The final voting results with respect to this Proposal were as follows: 8,507,660 votes for; 1,983,712 votes against; 141,682 votes abstaining; and 14,834,701 broker non-votes.
Proposal 4. The stockholders ratified the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2015. The final voting results with respect to this Proposal were as follows: 24,456,852 votes for; 778,319 votes against; 232,581 votes abstaining; and 0 broker non-votes.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is filed with this Current Report on Form 8-K: Exhibit No.
10.1 Caladrius Biosciences, Inc. 2015 Equity Compensation Plan (1)
I see it also! Hope we finish up!
I actually told some people to buy, at this price you can not go wrong! Yes it could be a wait BUT once they partner the price will go up, the same when Japan comes!
OMG there has been nothing to post good now for a while!
Caladrius Biosciences, Inc. (CLBS) ended the day Wednesday at $1.86, a loss of -1.59%, after trading at a volume of 397,551 shares and market cap of 96.63. Caladrius Biosciences, Inc. (CLBS) is performing below average at a weekly performance of -0.53% and a quarterly performance of -40.00% off their 52 week low by 3.33%. Caladrius Biosciences, Inc. (CLBS)’s monthly performance is -20.17% and for the upcoming day, Caladrius Biosciences, Inc. (CLBS) is a good stock in the Biotechnology industry with an averaged analyst rating of 2 and EPS growth this year of 11.60%
http://www.wallstreetscope.com/thursdays-morning-thoughts-sparton-corp-spa-tengasco-inc-tgc-caladrius-biosciences-inc-clbs-histogenics-corporation-hsgx-inovalon-holdings-inc-inov/25344436/
I have complained and wrote the company about this since the release of the nbs10 trial data! The new management started out good but it is the same thing NO PR! They could even be PRing the hell out of all there events and summit meetings>>BUT NOTHING! I even had posted a bunch of stuff I found about them and what they where doing not even listed on their site or a press release about and nothing. I even mentioned them having at least a chairman's blog 2 or 3 times a month>>>NOTHING! If you look back even 4 to 6 months ago here I was complaining about it.
Yes I have emailed him before and posted here, but what good does calling Eric do? I have asked him questions and he has answered them, he does not control company!
Things could change quickly with a few different things, but we all know that.(japan, partnerships, nbs10 getting fast tracked with outstanding results) We do how ever have some revenue coming in which most small Bio's don't have. The PCT division could pick up drastically with all the Pharms starting to get into the stem cell field plus the ones we have could start to increase orders! If you go to http://www.caladrius.com/investors/overview/ and click on the presentation, go to page 5 you will see here we have over 100 clients and the ones listed are big names!
They do not have any cholesterol drug that I know of! I know one of the comparisons made in a SA article compared the improvement to some of the statin drugs if that is what some are referring to? But I believe you are right in your statement on increasing blood flow!
I have to agree with you! They need to get the PPS up by partnership or something. If they would have another offering even in the $4 PPS range it would kill us!
BioFlash
How short sellers threaten innovations that could benefit patients
Jul 6, 2015, 7:00am EDT
Don Seiffert
Boston Business Journal http://www.bizjournals.com/boston/blog/bioflash/2015/07/how-short-sellers-threaten-innovations-that-could.html
Happy 4th everyone! Be safe!
I totally agree lunatic!! The names are outstanding in there fields, people like this do not waste there time unless they believe in what there doing!
Sorry for this joke ahead of time>>I can not believe I am agreeing with a lunatic! LOL sorry again!
You can find t new line-ups for the different scientific advisory boards for CLBS here>> http://www.caladrius.com/about/scientific-advisors/
Scientific Advisors
Melanoma Scientific Advisory Board
Robert O. Dillman, MD
Vice President, Oncology, Caladrius Biosciences
Michael Atkins, MD
Georgetown-Lombardi Comprehensive Cancer Center
Lisa Butterfield, PhD
University of Pittsburgh
Kim Margolin, MD
Fred Hutchinson Cancer Research Center
Steven O’Day, MD
Beverly Hills Cancer Center
Merrick Ross, MD
MD Anderson Cancer Center
Jedd Wolchok, MD, PHD
Memorial Sloan-Kettering Cancer Center
Immune Modulation Program Advisors
Robert A. Preti, PhD
Chief Scientific Officer - Caladrius Biosciences, and President - PCT, a Caladrius company
Jeffrey Bluestone, PhD
University of California, San Francisco, Diabetes Center
David A. Horwitz, MD
University of Southern California
Robert Korngold, PhD
Hackensack University Medical Center
Robert S. Negrin, MD
Stanford University
David Peritt, PhD
Hospira
Noel L. Warner, PhD
BD Biosciences
Cardiovascular Disease Scientific Advisors
Robert Harrington, MD
Stanford University
Timothy Henry, MD
Cedars-Sinai Heart Institute
Thomas Povsic, MD
Duke Clinical Research Institute
Arshed Quyyumi, MD
Emory Clinical Cardiovascular Research Institute
Richard Schatz, MD
Scripps Clinic
Christopher White, MD
Ochener Medical Center
Joseph Wu, MD
Stanford University
Andreas Zeiher, MD
Goethe University
I hate to say this BUT you are not suppose to advertise other boards on this one! That being said you CAN repost BUT not mention or give links to other boards! NOT MY RULES>>>But they are the rules here!
I am going to because you keep saying how good it is and I believe you, BUT I just got my first smart phone 1 week ago and I am actually discovering that it is smarter than me!!ROFLMAO I am dying to go on there and will as soon as I figure this phone out!!LOL
I wanted to post this on tis board. It is from another board I visit and is defiantly worth the read! The man posting jca408harvard is in the medical field and I have found his post to be right online so I wanted to re-post here his thoughts on CLBS! Remember this is just his opinion and should be taken as nothing more.
jca408harvard
• Jun 26, 2015 6:09 PM
How we went from $7 to $2 but will be at $10 by June 2016
The primary driver of the stock back in November ($7.23 pps) was the assumption that NBS10 (AMR-001) phase 2 data would be a success. CLBS10 (cardiac) did in fact have a successful phase 2 study in terms of morbidity and mortality. This is good in terms of eventual FDA approval but the trial design was incredibly poor. SPECT imaging to show perfusion at six months was an extremely risky endpoint at that early of a measurement. Angiogenesis takes time and the size of new vessels are extremely hard to detect initially (especially seeking such from a SPECT image). Phase 1 data showed significant perfusion improvements and management really overreached to try to match those results. Due to this overconfidence in the perfusion endpoint they focused far too strongly on that and severely neglected other measures (specifically dose dependency and cell yield) as ways to control confounding in the design phase of the trial. This was an enormous strategic error, left the treatment with good mortality data but no mechanistic insight, had a failed endpoint and led to a coordinated short attack that crushed the stock and has it currently broken.
Robin Smith was rightfully removed as CEO within 2 months of this debacle. In addition to her massive error in the trial design she also failed to secure long-term financing for the oncology and Tregs platforms when the stock was much higher. Again, this was based on her misguided overconfidence in the perfusion endpoint and it taking the pps much higher. The stock is now stuck in a series of easily identifiable manipulation and panic selling. It will only take a couple of good pieces of news to break the current cycle, cause a squeeze and give longs more courage to avoid panic and hold long. Those of us in the cardiac field know the potential of CLBS10 (the CXCR4 component is wonderful from biochemistry standpoint) so a partnership and a thoughtfully crafted trial design will come. Everything else with CLBS is very good.
The reason the stock is languishing right now is because it is currently broken. It is quite easily manipulated and leads to panic selling from longs who have already suffered significant losses. Any gains are walked back down with no catalysts in the immediate future...but CLBS is getting closer to those catalysts. The reason we didn't take a jump with the other biotechs today was because of our removal from the Russell Index. Here's how we get to $10 based on a late-July price of $2.50:
1.) CLBS10 (cardiac) partnership will happen. It is not a matter of if but when. The recent scientific advisory board is a top-notch, stellar group of cardiology experts. This is a direct preparation for partnership with application in multiple areas. This will add $2. I appreciate that Mazzo is taking his time with this to weigh all options in the partnership offers.
2.) CLBS03 (Tregs) are the platform that I am most excited about. Fantastic potential. Unfortunately, they are furthest from market right now. A partnership to begin its phase 2 trial must be near. The FDA has already approved the protocol and it doesn't do CLBS any good to have it currently not in development. This will add $2.
3.) CLBS will be cash positive by 4Q of this year. This adds $1.
4.) I am projecting 30% growth in PCT and am being conservative. This adds $1.50.
5.) I will assign a small $1 value to pure momentum of these events happening one after another.
We are clearly undervalued at this time because we have a phase 3, fully funded, fast-tracked immuno-oncology therapeutic and we are trading under $2.
We're trading at $1.87 but we are in really good shape for the future